Clinical Trial

OH2 Injection in Melanoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy of OH2 injection in patients with unresectable or metastatic melanoma who have failed at least second-line standard therapy, using investigator-selected salvage chemotherapy or best supportive care (BSC) as controls.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-11; most recent amendment 2025-07-22.
Trial Details
NCT Number NCT05868707
Lead Sponsor Binhui Biopharmaceutical Co., Ltd.
Conditions Melanoma
Enrollment 340 participants
Start Date 2023-03-08
Primary Completion 2026-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-07-25